Cortexyme lowers dose amid safety concerns, raising questions about future of offbeat Alzheimer’s approach
Late last month, Cortexyme announced a subset of patients saw their cognitive decline slow while taking the high dose of the company’s experimental Alzheimer …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
